ReviewFrontiers in psychiatry2026
Electroencephalography for early Alzheimer's disease diagnosis: from advanced feature engineering to interpretable ai and clinical translation.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This review aims to comprehensively review the methodologies and advancements in using electroencephalography (EEG) for the early diagnosis of Alzheimer's disease (AD), addressing the limitations of traditional diagnostic tools. Methods: We conducted a comprehensive analysis of current research, encompassing the complete EEG analysis pipeline from signal acquisition and preprocessing to feature extraction-including time-frequency and brain network metrics-and the application of machine learning and deep learning algorithms. Results: Characteristic EEG alterations, such as spectral slowing and reduced signal complexity, are associated with early AD. Advanced feature extraction combined with intelligent algorithms significantly enhances diagnostic performance, with some studies reporting classification accuracies exceeding 95%. Integration of EEG with multimodal data (e.g., MRI, genetic markers) further improves diagnostic robustness. Conclusions: EEG is a promising, non-invasive, and cost-effective tool for early AD detection in appropriate clinical and research settings. The integration of advanced signal processing with intelligent algorithms can significantly improves diagnostic precision, though clinical translation requires standardized protocols and validation on larger, diverse cohorts. Significance: This work highlights the potential of EEG to facilitate accessible, early-stage AD screening, which is crucial for timely intervention and may contribute to reducing the disease's future socioeconomic burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.